http://www.fresenius.com en-us Tue, 28 Feb 2012 09:35:57 GMT Tue, 28 Feb 2012 09:35:57 GMT http://blogs.law.harvard.edu/tech/rss OpenText Web Solutions 5 Fresenius is aiming for new record sales and earnings this year. Ulf Mark Schneider, CEO of Fresenius, confirmed the Group outlook 2012 at the company’s Annual General Meeting in Frankfurt today.

]]> Fresenius successfully placed 13.8 million new ordinary shares today.

]]> Fresenius resolved today to issue 13.8 million new ordinary shares from authorized capital excluding subscription rights.

]]> Fresenius Medical Care expects another record result for 2012. At the annual general meeting in Frankfurt am Main today, Dr. Ben Lipps, the company’s chief executive officer, confirmed the full-year outlook.

]]> The preliminary financial results, announced on April 26, 2012, remain unchanged. Based on the Group’s excellent financial results in the first quarter of 2012, Fresenius raises its guidance.

]]> Fresenius Medical Care AG & Co. KGaA, the world’s largest provider of dialysis products and services, today announced its results for the first quarter of 2012.

]]> Fresenius announced today its intention to make a voluntary public takeover offer to Rhön-Klinikum AG shareholders of €22.50 per share in cash. The total purchase price for all outstanding shares in the company is approximately €3.1 billion.

]]> Bad Homburg, Germany – Fresenius Medical Care AG & Co. KGaA (the “company” or “Fresenius Medical Care”; Frankfurt Stock Exchange: FME / New York Stock Exchange: FMS), the world’s largest provider of dialysis products and services, today announced its preliminary results for the first quarter of 2012.

]]> Fresenius Medical Care today announced the signing of an agreement with Toray Industries, Inc regarding exclusive development and marketing in Europe of an injectable form of TRK-820, an innovative antipruritic agent originated and developed by Toray. Under this agreement, Fresenius Medical Care will exclusively market the product in Europe once Toray receives approval for TRK-820 in the region.

]]> Fresenius Medical Care announced today that Fresenius Medical Care North America completed the sale of 45 dialysis clinics to Dialysis Newco, Inc. (“DSI Renal”). An additional ten clinics are expected to be sold to DSI Renal following receipt of state regulatory approvals.

]]> Fresenius successfully placed senior unsecured notes.

]]> HELIOS Kliniken GmbH has completed the acquisition of 94.7% of the share capital in Damp Group, following approval by local and antitrust authorities. Damp will be consolidated as of March 31, 2012.

]]> Fresenius today announced its intention to sell senior unsecured notes.

]]> Fresenius today announced changes to the company’s Management Board. The Supervisory Board of Fresenius Management SE has appointed Rice Powell and Mats Henriksson as new Management Board members, effective January 1, 2013.

]]> Fresenius Medical Care today announced a change in the Management Board. Rice Powell will succeed Dr. Ben J. Lipps as CEO of Fresenius Medical Care and Chairman of the Management Board, effective January 1, 2013.

]]> Fresenius SE & Co. KGaA has successfully completed the purchase of Fresenius Medical Care AG & Co. KGaA („FME“) ordinary shares, as announced on November 16, 2011. Fresenius purchased 3,500,000 FME ordinary shares.

]]> Fresenius Medical Care today announced that Fresenius Medical Care North America has closed the acquisition of Liberty Dialysis Holdings, Inc., the holding company of Liberty Dialysis and Renal Advantage. The closing follows the completion of the review of the transaction and issuance of a consent decree by the United States’ Federal Trade Commission.

]]> Standard & Poor’s has raised the corporate credit rating of Fresenius SE & Co. KGaA from BB to BB+. According to Standard & Poor’s, the upgrade primarily reflects the steady increase in Fresenius’ revenue diversification, profitability and cash flow generation in an adverse macroeconomic environment.

]]> Fresenius Medical Care today announced that Standard & Poor’s has upgraded the corporate credit rating of Fresenius Medical Care AG & Co. KGaA to ‘BB+’ from ‘BB’. In addition, the agency also raised the ratings of Fresenius Medical Care’s various unsecured senior notes to ‘BB+’ from ‘BB’.

]]> APP Pharmaceuticals, a subsidiary of Fresenius Kabi, has received a warning letter dated 22 February 2012 from the New York District FDA office regarding the Company’s Grand Island plant. The warning letter follows an inspection at the facility which concluded in July 2011.

]]> Ulf Mark Schneider, CEO of Fresenius, commented: “2011 was another highly successful year for Fresenius. Our group net income increased by 18% in constant currency after 23% growth in 2010. Based on these strong results we will propose the 19th consecutive dividend increase to our shareholders...”

]]> Fresenius Medical Care AG & Co. KGaA today announced its results for the fourth quarter and full year of 2011.

]]> Fresenius will continue the legal dispute concerning the payment of legal fees at the German Federal Court of Justice. The court granted Fresenius’ complaint against the Frankfurt am Main Higher Regional Court’s decision issued on February 15, 2011.

]]> Fresenius has Germany’s best career website, according to a new study published by the market research institute Potentialpark. The Fresenius career portal was ranked first place, followed by ThyssenKrupp and Deutsche Post DHL.

]]> Fresenius Medical Care successfully placed three tranches of U.S. dollar and euro-denominated senior unsecured notes (together the “senior notes”). Proceeds amounting to approximately $1.82 billion are intended to be used for acquisitions, including the acquisition of Liberty Dialysis Holdings, Inc., to refinance indebtedness and for general corporate purposes.

]]> Fresenius Medical Care today announced its intention to sell U.S. dollar and euro-denominated senior unsecured notes (together the “senior notes”) of $1.2 billion and €250 million. The tranches will have a maturity between 7.5 and 10 years.

]]>